

Inferior Vena Cava Filters

How Do We Move Forward?



Edward J. Arous, MD; and Louis M. Messina, MD

Despite their widespread use, the **indications** for the selective use of temporary inferior vena cava (IVC) filters remains **uncertain** with **few trials supporting their use**. Additionally, the **risks** of long-term temporary IVC filter insertion are being increasingly discussed amongst the **mainstream media** and through **multiple class action lawsuits**. **Retrievable** IVC filters were specifically designed to have a **less secure implantation** in order to facilitate retrieval. However, multiple reports have demonstrated **significant filter-related complications**, most commonly **related to duration** of implantation. Furthermore, the risk is **not isolated to one manufacturer** alone. The incidence of filter-related **complications is linearly related to its duration** of time on the market. Currently, the **FDA** recommends that IVC filters be **removed within 25-54 days** of their implantation. Unfortunately, **little evidence** exists to show that this recommendation is followed routinely. Recently, the **PRESERVE Trial** (NCT02381509) was initiated as a multicenter non-randomized open label study to determine the safety and effectiveness of commercially available IVC filters (both temporary and permanent) in individuals who **require mechanical prophylaxis** against pulmonary embolism. **Until such evidence** is developed, temporary IVC filters should be implanted based on best available evidence and routinely removed within the guidelines of the FDA of 25-54 days. A fair question at this point is whether the design features themselves that are required to manufacture a low profile removable IVC filter can achieve effective prophylaxis against pulmonary embolism at a low rate of short and long-term complications.

CHEST 2016; 149(5):1143-1145

KEY WORDS: deep venous thrombosis; inferior vena cava filter; pulmonary embolism

Unlike **temporary** inferior vena cava (IVC) filters, the **and** of the **permanent Greenfield** filter to **reduce** the risk of **pulmonary embolism** (PE) in patients suffering an acute DVT and who **be** is **well-established**. In a review of more than 3,000 consecutive patients, the **long-term patency of Greenfield** IVC filters is **98%**.¹

There are only two randomized controlled trials examining the use of permanent IVC filters.^{2,3} Fullen et al² randomized patients with hip fracture to either receive a permanent IVC **or** **,** but **s**.² The incidence of **in the** group was **,** whereas it was significantly lower in the **group ()**. The **of the**

ABBREVIATIONS: FDA = US Food and Drug Administration; IVC = inferior vena cava; PE = pulmonary embolism

AFFILIATIONS: From the Division of Vascular and Endovascular Surgery (Dr Arous) and Diabetes Center of Excellence and Division of Vascular and Endovascular Surgery (Dr Messina), University of Massachusetts Medical School, Worcester, MA.

CORRESPONDENCE TO: Louis M. Messina, MD, Diabetes Center of Excellence and Division of Vascular and Endovascular Surgery, University of Massachusetts Medical School, 55 Lake Ave N, Worcester, MA 01655; e-mail: Louis.Messina@umassmemorial.org

Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

DOI: <http://dx.doi.org/10.1016/j.chest.2016.03.015>

group (10%) was substantially lower than the nonfilter group (24%).

The Prevention du Risque d'Embolie Pulmonaire Par Interruption Cave (PREPIC) study showed that permanent IVC filters reduced the long-term incidence of PE by 68%, but had an 8.2% higher incidence of recurrent DVT.³ The goal of the PREPIC trial was to determine if the addition of a permanent IVC filter to conventional anticoagulation improved VTE outcomes in higher risk patients. However, in the United States, permanent IVC filters are not used routinely in patients with DVT who can tolerate anticoagulation. What is not well-established is the safety and efficacy of selective use of prophylactic, temporary IVC filters in special patient subgroups that are at high risk of VTE, but cannot receive prophylactic anticoagulation.

Despite their widespread use, the indications for the selective use of temporary IVC filters remain uncertain. To address this question, the American College of Chest Physicians has provided indications for the selective use of IVC filters.⁴ In addition, a recent publication by the Agency for Healthcare Research and Quality systematically reviewed the comparative effectiveness and safety of pharmacological and mechanical methods of prophylaxis of VTE in patients hospitalized with trauma, traumatic brain injury, burns, or liver disease; patients on antiplatelet therapy; obese or underweight patients; patients having obesity surgery; or patients with acute or chronic renal failure.⁵ These special subpopulations have unequal risks for bleeding and thrombosis and may benefit differently from prophylactic therapy. This comprehensive analysis revealed a paucity of high-quality evidence to inform the use of temporary IVC filters in these patients.

This lack of trials to support indications for the selective use of temporary filters only further amplifies the concern about their long-term complication rates. The risks of long-term temporary IVC filter insertion have been recently discussed among the mainstream media as well. Lawsuits, initially against C.R. Bard, have raised the concern that certain temporary IVC filters are more prone to complications than others. Even the development of websites such as www.ivcfilterlawsuit2015.com, has influenced medical decision-making. Are certain temporary IVC filters more prone to complications than others? Does their risk-benefit ratio support their widespread use?

Retrievable, temporary IVC filters began to appear on the market in the early 2000s. They were specifically

designed to have a less secure implantation to facilitate retrieval. In 1999, the US Food and Drug Administration (FDA) downgraded the risk of IVC filters from class III to class II, thereby permitting manufacturers to achieve market approval more readily under the assumption that new filters are substantially equivalent to other legally marketed devices.⁶ As a consequence, several retrievable IVC filters were submitted to the FDA and approved as permanent filters with an option for retrieval. However, there have since been multiple reports demonstrating significant complications, including vena caval penetration, filter embolization, recurrent VTE, and caval thrombosis. In 2010, the FDA disclosed that retrievable IVC filters had been associated with more than 900 adverse events⁷; therefore, in 2014, the FDA released updated recommendations in which physicians were advised to remove filters within 25 to 54 days of their implantation.⁸ Little evidence exists to show that this recommendation is followed routinely.

Recent lawsuits have been directed against the C.R. Bard Recovery and G2 filters. In 2007, a single-institution review of patients with a Bard Recovery filter by noncontrast CT revealed a 21% incidence of filter arm fracture or migration as well as increased incidence of limb perforation of the vena cava over time.⁹ Additionally, other studies have continued to show that the risk of temporary IVC filter complications is linearly related to the duration of time on the market.^{10,11} A 44-year retrospective review of 9,002 patients with 15 types of filters demonstrated a 19% incidence of caval penetration, of which 19% had significant organ and structural involvement.¹² However, the risks are not isolated to Bard filters alone. A review of 50 Gunther Tulip and 27 Celect filters demonstrated an 86% caval perforation of at least one filter component on CT scan.¹² Additional studies have continued to report that smaller IVC diameters and longer indwell times had higher rates of IVC penetration,¹³ regardless of the manufacturer.

In addition to their complication rates, little evidence exists to show that temporary IVC filters are being retrieved routinely. Although a single-center review of the filter retrieval reported a 90.6% success rate,¹⁴ this retrieval rate is not achieved uniformly. Most estimates of temporary IVC filter retrieval hover around 20%, whereas a systematic review found an average retrieval rate of 34%,¹⁵ leaving these patients at risk for late complications, and worse, most of these patients likely become lost to follow-up.

An additional concern is the risk of recurrent VTE in patients after filter retrieval? Two single-institution, retrospective studies have demonstrated a 2.8% to 6.6% risk of recurrent or worsening VTE, and 2.6% risk of PE resulting in death.^{16,17} Overall, the risk of VTE was low, but is most prevalent in patients with VTE at the time of filter implantation.

With all of these concerns, how do we move forward? Acknowledging the difficulties of conducting randomized controlled trials of this vulnerable patient population, it is recommended that robust observational studies be undertaken that control for confounding by indication and disease severity. Recently, the Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) Trial (NCT02381509) was initiated as a multicenter nonrandomized open label study to determine the safety and effectiveness of commercially available IVC filters (both temporary and permanent) in individuals who require mechanical prophylaxis against PE. Until such evidence is developed, use of temporary IVC filters should be implanted based on best available evidence and routinely removed within the guidelines of the FDA (25 to 54 days). At this time, the type and duration of follow-up of the patients in whom the filter could not be removed remains unknown. A fair question at this point is whether the design features themselves that are required to manufacture a low profile removable IVC filter can achieve effective prophylaxis against PE at a low rate of short- and long-term complications.

Acknowledgments

Financial/nonfinancial disclosure: None declared.

References

- Proctor MC, Greenfield L. Thirty-year Greenfield filter experience: are temporary filters needed? *Vascular*. 2004;12(Suppl 1):S18.
- Fullen WD, Miller EH, Steele WF, McDonough JJ. Prophylactic vena caval interruption in hip fractures. *J Trauma*. 1973;13(5):403-410.
- Greenfield LJ. The PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) Randomized Study. *Perspect Vasc Surg Endovasc Ther*. 2006;18(2):187-188.
- Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):7S-47S.
- Singh S, Haut ER, Brotman DJ, et al. *Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations*. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
- Guidance for cardiovascular intravascular filter 510(k) submissions. 1999. <http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073777.pdf>. Accessed March 21, 2016.
- Removing retrievable inferior vena cava filters: initial communication. 2010. <http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm221676.htm>. Accessed March 21, 2016.
- Morales JP, Li X, Irony TZ, Ibrahim NG, Moynahan M, Cavanaugh KJ Jr. Decision analysis of retrievable inferior vena cava filters in patients without pulmonary embolism. *J Vasc Surg Venous Lymphat Dis*. 2013;1(1):376-384.
- Hull JE, Robertson SW. Bard Recovery filter: evaluation and management of vena cava limb perforation, fracture, and migration. *J Vasc Interv Radiol*. 2009;20(1):52-60.
- Vijay K, Hughes JA, Burdette AS, et al. Fractured Bard Recovery, G2, and G2 express inferior vena cava filters: incidence, clinical consequences, and outcomes of removal attempts. *J Vasc Interv Radiol*. 2012;23(2):188-194.
- Andreoli JM, Lewandowski RJ, Vogelzang RL, Ryu RK. Comparison of complication rates associated with permanent and retrievable inferior vena cava filters: a review of the MAUDE database. *J Vasc Interv Radiol*. 2014;25(8):1181-1185.
- Durack JC, Westphalen AC, Kekulawela S, et al. Perforation of the IVC: rule rather than exception after longer indwelling times for the Gunther Tulip and Celect retrievable filters. *Cardiovasc Intervent Radiol*. 2012;35(2):299-308.
- Lee JK, So YH, Choi YH, et al. Clinical course and predictive factors for complication of inferior vena cava filters. *Thromb Res*. 2014;133(4):538-543.
- Renno A, Khateeb F, Kazan V, et al. A single center experience with retrievable IVC filters. *Vascular*. 2015;23(4):350-357.
- Angel LF, Tapson V, Galgon RE, Restrepo MI, Kaufman J. Systematic review of the use of retrievable inferior vena cava filters. *J Vasc Interv Radiol*. 2011;11(22):1522-1530.e1523.
- Yamagami T, Tanaka O, Yoshimatsu R, Miura H, Nishimura T. Venous thromboembolism after removal of retrievable inferior vena cava filters. *Cardiovasc Intervent Radiol*. 2010;33(1):74-79.
- Yavuz K, Geyik S, Hoppe H, Kolbeck KJ, Kaufman JA. Venous thromboembolism after retrieval of inferior vena cava filters. *J Vasc Interv Radiol*. 2008;19(4):504-508.